Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00285415 · ClinicalTrials.gov registry record · Phase 2

A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation

A Phase 2 study, sponsored by Carilion Clinic.

Terminated
Registry status
Phase 2
Development phase
46
Enrollment target

NCT00285415: Clinical Trial Phase 2 study, sponsored by Carilion Clinic.

NCT00285415 is a Phase 2 study that was terminated before completion, run by Carilion Clinic. The registered enrollment target is 46 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00285415, a Phase 2 study, was terminated before completion, sponsored by Carilion Clinic.

TERMINATED
Registry status
Phase 2
Development phase
46 participants
Enrollment target

Study Summary

The purpose of this study is to determine the effectiveness of the combination of the two drugs, docetaxel (Taxotere®) and carboplatin (Paraplatin®) followed by radiation directed at the tumor in treating your endometrial cancer.

Primary Outcome

to estimate the overall response rate (ORR) for women with newly diagnosed stages III-IV or recurrent endometrial carcinoma treated with docetaxel and carboplatin followed by tumor volume directed pelvic plus or minus para-aortic irradiation.

Interventions

  • DRUG Docetaxel and Carboplatin

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2005-04
Est. Completion 2012-06
Phase Phase 2
Carilion Clinic

45 total trials

Why NCT00285415 stopped before completion

NCT00285415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).

The record links to 0 conditions, and to 1 intervention - of which Docetaxel and Carboplatin is the first listed.

NCT00285415 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00285415 about?

NCT00285415 is a clinical study titled "A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation". The purpose of this study is to determine the effectiveness of the combination of the two drugs, docetaxel (Taxotere®) and carboplatin (Paraplatin®) followed by radiation directed at the tumor in treating your endometrial cancer.

What is the current status of trial NCT00285415?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2005-04. Estimated completion is 2012-06.

What interventions are being tested in trial NCT00285415?

The interventions under investigation include: Docetaxel and Carboplatin (DRUG).

Who is sponsoring clinical trial NCT00285415?

This trial is sponsored by Carilion Clinic, which has 45 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00285415's enrollment target sits among peer trials

46 1286th of 2000 higher than 705 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00285415, the US trial registry maintained by the National Library of Medicine. NCT00285415 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.